Biotech · Private company
BrightGene Bio-Medical Technology Co., Ltd.
Track this companyFree. Adds BrightGene Bio-Medical Technology Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- BGM0504Phase 1 · Non-diabetic Overweight or ObeseClinicalTrials.gov · fetched Nov 12, 2026
- BGM1812Phase 1 · HealhtyClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.Phase 1 · Non-diabetic Overweight or ObeseClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.Phase 1 · Non-diabetic Overweight or ObeseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and WomenPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 9, 2025ClinicalTrials.gov NCT07224399 · fetched Nov 12, 2026
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsPHASE1 · COMPLETED · started Aug 11, 2025ClinicalTrials.gov NCT07166081 · fetched Nov 12, 2026
- Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsPHASE1 · COMPLETED · started Oct 21, 2024ClinicalTrials.gov NCT06714955 · fetched Nov 12, 2026